** Shares of Compass Pathways CMPS.O rise 27% to $7.39 premarket

** Co says its experimental therapy, COMP360, helped people with treatment‑resistant depression, a hard‑to‑treat form of the illness

** Co says two late‑stage trials showed higher doses of COMP360 improved symptoms more than a low dose or placebo

** Co says patients given two doses three weeks apart showed meaningful six‑week improvement, with benefits seen as early as the next day

** Side effects such as headache, nausea and anxiety were mostly mild or moderate, says co

** Co plans to meet U.S. FDA and aims to file for approval later this year

** Shares rose ~83% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))